Trent R. Hummel, MD
- Co-Medical Director, Brain Tumor Center
- Professor, UC Department of Pediatrics
- trent.hummel@cchmc.org
- Board Certified
About
Biography
I completed my graduate medical training at the University of Cincinnati College of Medicine, residency training in pediatrics at Children's Hospital Medical Center of Akron, and pediatric hematology/oncology training at Cincinnati Children's Hospital Medical Center. Currently, I serve as an associate professor of pediatrics at Cincinnati Children's within the University of Cincinnati.
My clinical and academic interests focus on children and families affected by central nervous system tumors. I am a member of the Central Nervous System (Brain Tumor) Committee in the Children's Oncology Group (COG) and the co-principal investigator for the Pediatric Brain Tumor Consortium (PBTC) at Cincinnati Children's. My work is dedicated to developing novel therapeutics to treat children with all central nervous system tumors, including those with neurofibromatosis type 1 and 2 related CNS tumors and very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
BS: Eastern Mennonite University, Harrisburg, VA, 1997.
MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2001.
Residency: Children’s Hospital Medical Center of Akron, Akron, OH, 2004.
Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007; Research Fellow, Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, 2008.
Certification: American Board of Pediatrics, 2004; Pediatrics, 2004; Pediatric Hematology / Oncology, 2011.
Services and Specialties
Cancer and Blood Diseases, Brain Tumor, Neurofibromatosis, Rasopathy
Research Areas
Oncology, Cancer and Blood Diseases
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. Neuro-Oncology. 2022; 24:1598-1608.
Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report. Neuro-Oncology Advances. 2022; 4:vdac055.
Overcoming barriers to establishing autopsy procurement programs in pediatric patients with central nervous system tumors: a call to develop regional centers. Journal of Neuro-Oncology. 2021; 152:107-114.
Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. Acta Neuropathologica Communications. 2020; 8:182.
Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study. Journal of American Association for Pediatric Ophthalmology and Strabismus. 2020; 24:349.e1-349.e5.
A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Journal of Neuro-Oncology. 2020; 149:511-522.
From the Blog
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey